PathAI has announced the launch of MET Predict, an innovative AI-powered algorithm designed to transform the assessment of non-small cell lung cancer (NSCLC) tumors. This tool, integrated into the AISightⓇ Image management system, enables pathologists to identify tumors more likely to have MET exon 14 skipping (METex14) or MET amplification from H&E whole slide images, addressing a critical need in the diagnosis and treatment of NSCLC.
NSCLC accounts for about 85% of lung cancer cases, with METex14 mutations present in 3-4% of these cases. MET amplification, found in 1-6% of NSCLC cases, is emerging as a potential biomarker for targeted therapies. Traditional methods for detecting these alterations are often hindered by high costs, lengthy procedures, and the need for specialized equipment, making MET Predict's efficient and cost-effective approach a significant advancement.
The algorithm demonstrates a remarkable ability to identify over 90% of MET altered tumors and could conserve tissue in 30% of cases with low likelihood of MET alteration. This capability not only streamlines the biomarker evaluation process but also enhances the molecular testing paradigm, offering pathologists rapid and precise insights directly from H&E images.
Dr. Andy Beck, co-founder and CEO of PathAI, highlighted the tool's potential to improve the efficiency of NSCLC tumor assessments and the accuracy of identifying genetic alterations. By expanding AISight's capabilities, MET Predict addresses the pathology labs' need for accessible and comprehensive molecular tools that deliver actionable insights from biopsy samples, potentially reducing diagnostic time and resources while improving assessment accuracy.
Currently designated for Research Use Only, MET Predict and AISight are not yet approved for diagnostic procedures. Nonetheless, their introduction signifies a pivotal moment in the application of AI technology in healthcare, particularly in cancer diagnostics. This development could democratize access to advanced molecular insights, paving the way for more personalized treatment strategies for lung cancer patients.
The integration of AI tools like MET Predict into healthcare reflects a broader trend towards enhancing diagnostic accuracy and efficiency. For oncologists and pathologists, MET Predict offers a promising addition to their diagnostic arsenal, with the potential to streamline workflows, expedite biomarker evaluations, and identify candidates for targeted therapies more effectively.
As PathAI continues to lead in AI-powered pathology solutions, the launch of MET Predict underscores the company's commitment to advancing diagnostic accuracy and operational efficiency in pathology labs globally. The implications of this technology for patient care and the progression of precision medicine in oncology are profound, marking a noteworthy development in the field.
